Become a Member
  • Track your favourite stocks
  • Create & monitor portfolios
  • Daily portfolio value
Sign Up
Quickpicks
Add shares to your
quickpicks to
display them here!

IN BRIEF: PureTech notes Akili's results for EndeavorRx ADHD trial

4th May 2023 11:46

PureTech Health PLC - Boston-based biotechnology company - Says its founded entity, Akili, announced clinical trial for video game-based therapy, EndeavorRx, showed improvement in attention and quality of life for people with attention deficit hyperactivity disorder. Notes attention improved in more than 80% of adults with ADHD, while over a third of participants "no longer exhibited an attention deficit following treatment."

EndeavorRv is the only US Food & Drug Administration authorised treatment delivered through video game experience. It is meant to improve attention function in children with ADHD. Data from trial on adults will be submitted to the FDA later this year.

Current stock price: 218.50 pence, trading flat on Thursday

12-month change: up 30%

By Sabrina Penty; Alliance News reporter

Comments and questions to [email protected]

Copyright 2023 Alliance News Ltd. All Rights Reserved.

FTSE 100 Latest
Value7,967.99
Change36.01